GSBR-1290
Aliases: GSBR1290 · oral small-molecule GLP-1R agonist
GSBR-1290 is a oral peptide/small molecule peptide targeting GLP-1R, developed by Structure Therapeutics for undisclosed indications. As of Aug 15, 2024, its highest verified stage is Phase 2.
Phase 2· verified Aug 15, 2024
Identity
- Generic name
- —
- Brand names
- —
- Development codes
- GSBR-1290
- Sponsor / originator
- Structure Therapeutics
- Targets
- GLP-1R
- Route / formulation
- Oral tablet
Development timeline
Trials
View all →| Registry ID | Phase | Status | Enrollment | Completion |
|---|---|---|---|---|
| StructureTx-GSBR1290-Ph1 | Phase 1 | Completed | 120 | Sep 1, 2023 |